Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016

Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016
Published Jul 13, 2016
74 pages — Published Jul 13, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016, provides in depth analysis on Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics.

The report provides comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)
- The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focu

  
Source:
Document ID
GMDHC0390TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Toll Like Receptor 8 (CD288 or TLR8) Overview71
Therapeutics Development84
  Toll Like Receptor 8 (CD288 or TLR8) Products under Development by Stage of Development81
  Toll Like Receptor 8 (CD288 or TLR8) Products under Development by Therapy Area91
  Toll Like Receptor 8 (CD288 or TLR8) Products under Development by Indication102
Toll Like Receptor 8 (CD288 or TLR8) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Toll Like Receptor 8 (CD288 or TLR8) Products under Development by Companies143
Toll Like Receptor 8 (CD288 or TLR8) Therapeutics Assessment177
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action182
  Assessment by Route of Administration202
  Assessment by Molecule Type222
Toll Like Receptor 8 (CD288 or TLR8) Companies Involved in Therapeutics Development249
  3M Drug Delivery Systems241
  Foamix Pharmaceuticals Ltd.251
  Folia Biotech Inc.261
  Galderma S.A.271
  Idera Pharmaceuticals, Inc.281
  MedImmune, LLC291
  Merck &Co., Inc.301
  Resolve Therapeutics, LLC311
  VentiRx Pharmaceuticals, Inc.321
Toll Like Receptor 8 (CD288 or TLR8) Drug Profiles3326
  854-A Drug Profile331
  Drug 1 to Agonize TLR7 and TLR8 for Oncology Drug Profile341
  Drug 2 to Agonize TLR7 and TLR8 for Oncology Drug Profile351
  Drug to Agonize TLR7 and TLR8 for Oncology Drug Profile361
  imiquimod Drug Profile371
  IMO-8400 Drug Profile386
  IMO-9200 Drug Profile442
  JB-6121 Drug Profile461
  leishmaniasis vaccine Drug Profile471
  MEDI-9197 Drug Profile481
  motolimod Drug Profile494
  resiquimod Drug Profile531
  RSLV-132 Drug Profile542
  Small Molecules to Agonize TLR7/8/9 for Cancer, Alzheimer's Disease and Infectious Disease Drug Profile561
  VTX-1463 Drug Profile571
  VTX-294 Drug Profile581
Toll Like Receptor 8 (CD288 or TLR8) Dormant Projects591
Toll Like Receptor 8 (CD288 or TLR8) Discontinued Products601
Toll Like Receptor 8 (CD288 or TLR8) Featured News &Press Releases6112
  May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference611
  Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study611
  Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom s Macroglobulinemia621
  Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis631
  Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom s Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting641
  May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors642
  Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer661
  Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma661
  Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia671
  Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting672
  Nov 06, 2014: Idera Pharmaceuticals Announces Upcoming Presentations of Data on IMO-8400 From Oncology Programs at Key Scientific Meetings691
  Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200701
  Sep 03, 2014: Ludwig Cancer Research And Cancer Research Institute Collaborate On Evaluation Of Ventirx's Investigational Immunotherapy701
  Sep 02, 2014: VentiRx Pharmaceuticals Announces Fast Track Designation Granted for Motolimod (VTX-2337), a Novel Immunotherapy for Women with Ovarian Cancer711
  Aug 08, 2014: Idera Pharmaceuticals and The Myositis Association Join Forces to Advance the Clinical Development of a Novel TLR Antagonist, IMO-8400, for the Treatment of Myositis721
Appendix732
  Methodology731
  Coverage731
  Secondary Research731
  Primary Research731
  Expert Panel Validation731
  Contact Us731
  Disclaimer741

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016" Jul 13, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Toll-Like-Receptor-8-CD288-or-TLR8-Pipeline-Review-H2-2016-2088-16197>
  
APA:
Global Markets Direct - Market Research. (2016). Toll Like Receptor 8 (CD288 or TLR8) - Pipeline Review, H2 2016 Jul 13, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Toll-Like-Receptor-8-CD288-or-TLR8-Pipeline-Review-H2-2016-2088-16197>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.